Global Antibacterial Drugs Market 2017-2027

抗菌薬の世界市場

◆タイトル:Global Antibacterial Drugs Market 2017-2027
◆商品コード:VGAIN705057
◆調査・発行会社:visiongain
◆発行日:2017年3月
◆ページ数:304
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Sigle User(1名閲覧)GBP2,499 ⇒換算¥374,850見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥449,850見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥749,850見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

当調査レポートでは、抗菌薬の世界市場について調査・分析し、抗菌薬の世界市場規模、市場動向、市場予測、関連企業情報などを含め、以下の構成でお届けいたします。
・レポートの概要
・イントロダクション
・抗菌薬の世界市場
 (市場規模予測、市場動向、市場の成長要因・阻害要因など)
・抗菌薬の世界市場:セグメント別市場分析
・抗菌薬の世界市場:地域別市場分析、市場規模予測
・市場環境分析
・専門家の見解
・主要企業分析
・結論

The global antibacterial drugs market is expected to grow at a CAGR of 1.3% in the first half of the forecast period and a CAGR of 3.1% in the second half of the forecast period. The market is estimated at $41.76bn in 2016 and $44.54bn in 2021.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 304-page report you will receive 124 tables and 97 figures – all unavailable elsewhere.

The 304-page report provides clear detailed insight into the global antibacterial drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope
• Global Antibacterial Drugs Market forecasts from 2017-2027

• Revenue forecasts for the 6 leading submarkets from 2017-2027:
- Cephalosporins
- Penicillins
- Fluoroquinolones
- Macrolides
- Carbapenems
- Others

• Revenue forecasts for the 43 leading marketed antibacterial drugs from 2017-2027:
- Cephalosporins: Rocephin, Sulperazon, Ceftin/Zinnat, Meiact, Flomox, Teflaro, Zeftera, Ceftolozane-tazobactam, Ceftazidime-Avibactam
- Penicillins: Generic amoxicillin, Augmentin, Zosyn/Tazocin, Unasyn, Generic amoxicllin-clavulanic acid, Amoxil
- Fluoroquinolones: Avelox, Cravit, Vigamox, Ciprodex, Cipro/Ciprobay, Geninax, Defafloxacin
- Macrolides: Biaxin/Clarith, Zithromax, Dalacin, Dificid, Solithromycin
- Carbapenems: Invanz, Merrem/Meropen, Primaxin, Doribax
- Other antibacterial drugs: Zyvox, Cubicin, Tygacil, TOBI/TIP, Solodyn, Vibativ, Sirturo, Tedizolid, Oritavancin, Dalbavancin, Nemonoxacin, Surotomycin

• Revenue forecasts for the leading developed and emerging national and regional markets. Markets forecasted in this report are the following:
- The US
- The EU: France, Germany, Italy, Spain, the UK, and others
- Japan
- The BRIC countries: Brazil, Russia, India, China
- South Korea
- The Rest of the World

• Analysis of the strengths, weaknesses as well as the opportunities and threats of the antibacterial drugs industry and market

• Coverage of antibacterial drug candidates in the R&D pipeline. Discussions of research and development – see progress in this industry, finding technological, clinical and commercial outlooks and opportunities

Visiongain’s study is intended for anyone requiring commercial analyses for the Global Antibacterial Drugs Market. You find data, trends and predictions.

Buy our report today Global Antibacterial Drugs Market 2017-2027: Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, Carbapenems and Others.

【レポートの目次】

1. Report Overview
1.1 Overview of Findings
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analysis
1.5 Who is This Study For?
1.6 Research and Analysis Methods
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports

2. Introduction to Antibacterial Drugs
2.1 Types of Bacterial Infection
2.2 Main Bacteria Causing Infections in Human Beings
2.3 Incidence and Mortality Profiles for Common Bacterial Infection
2.4 Treating Infections
2.4.1 The History of Antibacterial Drug Development
2.4.2 Mechanisms of Action
2.4.3 Leading Classes of Antibacterial Medicines
2.4.3.1 Cephalosporins
2.4.3.2 Penicillins
2.4.3.3 Carbapenems
2.4.3.4 Fluoroquinolones
2.4.3.5 Macrolides
2.4.4 Antibacterial Drug Resistance

3. Antibacterial Drugs: World Market 2017-2027
3.1 Antibacterial Drugs Revenues Plateau between 2011 and 2016
3.2 Antibacterial Agents – Market Segmentation
3.3 Antibacterial Drugs Market Forecast 2017-2027: Decline in Revenues for Fluoroquinolones
3.4 Drivers and Restraints in the Antibacterial Drugs Market, 2017-2027
3.5 Generic Erosion and Prescription Control Will Limit Market Growth
3.6 Changes in that Industry Sector’s Market Shares, 2017-2027
3.7 Pfizer is the Leader in the Antibacterial Drugs Market, 2016
3.8 Fragmented Market to Fracture Further

4. Cephalosporins Market Forecast 2017-2027
4.1 Cephalosporins Market 2016 – No Dominant Brands
4.1.1 Late-Stage Cephalosporins to Gain Market Share Between 2017 and 2027
4.1.2 Basilea, Merck, Actavis and AstraZeneca to Lead the Cephalosporins Market Between 2017 and 2027
4.1.3 Drivers and Restraints on the Cephalosporins Market, 2017-2027
4.1.4 Cephalosporins Lack Market Exclusivity
4.1.5 Strong Pipeline for Novel Cephalosporins
4.1.6 Rocephin (Roche) – The Only Treatment for Gonorrhoea in the US
4.1.6.1 Off Patent but Still Effective
4.1.6.2 Declining Revenues Owing to Competition – Forecast 2017-2027
4.1.7 Sulperazon – India’s Leading Treatment for RTIs and UTIs
4.1.7.1 Continued Growth in the Emerging Markets, Revenue Forecast 2017-2027
4.1.8 Zinnat/Ceftin – GSK’s Established Cephalosporin
4.1.8.1 Continued Decline in Revenue – Forecast 2017-2027
4.1.9 Meiact – A Broad Range Community Antibiotic
4.1.9.1 Spectracef Sales in the US Leads to Pass the Product
4.1.9.2 Competition in Japan to Hinder Growth – Revenue Forecast 2017-2027
4.1.10 Flomox – Shionogi’s Third-Generation Cephalosporin
4.1.10.1 Patent Issues and Litigation
4.1.10.2 Genericization and Safety to Restrict Sales – Forecast 2017-2027
4.1.11 Zinforo/Teflaro (Ceftaroline Fosamil): The First of the Fifth- Generation Cephalosporins
4.1.11.1 Unmet Needs in Pneumonia to Drive Growth – Revenue Forecast 2017-2027
4.1.12 Zeftera (ceftobiprole): Approved for Pneumonia in Europe
4.1.12.1 Future Sales Dictated by US Approval – Revenue Forecast 2017-2027
4.1.13 CXA-201 (Ceftolozane-Tazobactam): The Next Blockbuster Antibacterial
4.1.13.1 Broad Label and Spectrum of Activity Leads to Rapid Uptake – Revenue Forecast 2017-2027
4.1.14 CAZ-AVI (Ceftazidime-Avibactam): Approved in 2015
4.1.14.1 Competition from CXA-201 to Limit Sales – Forecast 2017-2027

5. Penicillins Market Forecast 2017-2027
5.1 Generics and Augmentin Dominate the Penicillins Market in 2016
5.2 Augmentin to Lose its Dominance over the Coming 10 Years – Market Shares for Penicillin Drugs, 2017-2027
5.3 Penicillin Antibacterial Drugs: Market Forecast 2017-2027
5.4 Drivers and Restraints for the Penicillin Market 2017-2027
5.5 Augmentin – Blockbuster Facing Generic Competition
5.5.1 Augmentin – Challenges in Some Countries
5.5.2 Stable Revenues Regardless of Generic Competition
5.5.3 Revenue Forecast 2017-2027
5.6 Zosyn/Tazocin (Piperacillin-Tazobactam) – Pneumonia Therapeutic
5.6.1 Patent Expiry and Revenue Extension for Pfizer
5.6.2 Historic and Current Revenue Performance
5.6.3 Revenue Forecast 2017-2027
5.7 Unasyn – Gram-negative and Positive Antibiotic
5.7.1 Falling Revenues – Forecast 2017-2027
5.8 Amoxil (Amoxicillin) – A Historic Antibacterial Brand
5.8.1 Marginal Decline in Revenue – Forecast 2017-2027
5.9 Generic Amoxicillin
5.9.1 Revenue Forecast 2017-2027
5.10 Generic Amoxicillin-Clavulanic Acid
5.10.1 Revenue Forecast 2017-2027

6. Fluoroquinolone Market Forecast 2017-2027
6.1 The Fluoroquinolone Market 2016
6.2 Changing Market Share for Fluoroquinolone Antibacterial Drugs, 2017-2027
6.3 Fluoroquinolone Antibacterial Drugs: Market Forecast 2017-2027
6.4 Trends in the Fluoroquinolone Market
6.4.1 Safety Fears for Fluoroquinolones
6.4.2 Avelox Patent Cliff
6.4.3 Inhaled Fluoroquinolone Formulations
6.5 Fluoroquinolone Market Forecast 2017-2027
6.6 Avelox
6.6.1 Safety Profile Hampers Sales
6.6.2 Generic Competition
6.6.3 Revenue Forecast 2017-2027
6.7 Cravit and Levaquin
6.7.1 Generic Competition Affecting Revenue Worldwide
6.7.2 Lifecycle Management for Cravit and Levaquin
6.7.3 Revenue Forecast 2017-2027
6.8 Vigamox
6.8.1 Branded and Generic Challenges 2011-2016
6.8.2 Moxeza: A Next-Generation Form of Vigamox
6.8.3 Revenue Forecast 2017-2027
6.9 Ciprodex and Cipro – Two Preparations of Ciprofloxacin
6.9.1 Ciprodex: A Second-Generation Ophthalmic Antibiotic
6.9.1.1 Revenue Forecast 2017-2027
6.9.2 Cipro Revenue Forecast 2017-2027: Continued Generic Erosion
6.10 Geninax
6.10.1 Revenue Forecast 2017-2027
6.11 Delafloxacin
6.11.1 Revenue Forecast 2017-2027

7. Macrolide Market Forecast 2017-2027
7.1 Macrolide Market in 2016
7.2 Changing Market Share for Macrolides, 2017-2027
7.3 Macrolide Antibacterial Drugs: Market Forecast 2017-2027
7.4 Trends in the Macrolide Market
7.5 Biaxin/Clarith
7.5.1 Past Revenue 2011-2015
7.5.2 Lifecycle Management for Continued Market Presence
7.5.3 Revenue Forecast 2017-2027
7.6 Zithromax
7.6.1 Concerns Over Safety and Marketing in the US
7.6.2 Effectiveness in Drug-Resistant Strains
7.6.3 Revenue Forecast 2017-2027
7.7 Dalacin
7.7.1 Revenue Forecast 2017-2027
7.8 Dificid
7.8.1 Rapid Uptake Slowed by High Cost
7.8.2 New Approvals and Expanded Indications
7.8.3 Revenue Forecast 2017-2027
7.9 Solithromycin
7.9.1 Revenue Forecast 2017-2027

8. Carbapenem Market Forecast 2017-2027
8.1 Carbapenem Market 2016
8.2 Changing Market Share for Carbapenems, 2017-2027
8.3 Carbapenem Antibacterial Drugs: Market Forecast 2017-2027
8.4 Trends in the Carbapenem Market
8.4.1 Rising Prevalence of Carbapenemases and β-Lactamases
8.4.2 No New Carbapenems in Late-Stage Trials
8.5 Merrem/Meropenem
8.5.1 Generics Affecting Revenue Worldwide
8.5.2 Revenue Forecast 2017-2027
8.6 Primaxin
8.6.1 Combination Therapy for Lifecycle Management
8.6.2 Historic and Current Revenues
8.6.3 Revenue Forecast 2017-2027
8.7 Invanz
8.7.1 Revenue Forecast 2017-2027
8.8 Doribax
8.8.1 Doribax in HAP and VAP
8.8.2 Lifecycle Management in Japan and the Rest of the World
8.8.3 Revenue Forecast 2017-2027

9. Other Antibacterial Drugs Forecast 2017-2027
9.1 The Market for Other Classes of Antibacterial Drugs
9.2 Changing Market Share for Fluoroquinolone Antibacterials 2017-2027
9.3 Other Antibacterials: Market Forecast 2017-2027
9.4 Trends in the Other Classes of Antibacterial Drugs
9.4.1 New Oxazolidinones Will Drive Growth
9.4.2 New Drug Classes to Drive Submarket Growth to 2027
9.5 Zyvox – The Market Leading Antibacterial
9.5.1 MRSA Activity Driving Revenue Growth
9.5.2 Promise in Tuberculosis and Anthrax
9.5.3 Patents, Litigation, and Competition – When and Who Will Produce Generic Linezolid?
9.5.4 Flat Growth to Patent Expiry, Revenue Forecast 2017-2027
9.6 Cubicin – The Leading Brand for ABSSSIs
9.6.1 Revenue Boosted by Approvals Worldwide
9.6.2 Patents, Litigation and Deals – How Long Will Market Exclusivity Last?
9.6.3 Sustained Growth through to 2021, Revenue Forecast 2017-2027
9.7 Tygacil – A Tetracycline with Many Approved Indications
9.7.1 Concerns Limiting Revenue Potential
9.7.2 Competition from Other Therapies Restricts Growth: Revenue Forecast 2017-2027
9.8 TOBI/TOBI Podhaler – The Market Leading Inhaler for Cystic Fibrosis
9.8.1 Historic and Current Revenue Performance
9.8.2 Approvals and Launches in New Markets to Drive Revenue Growth
9.8.3 Competition to Limit Long-term Growth, Revenue Forecast 2017-2027
9.9 Solodyn – A Treatment for Severe Acne
9.9.1 Generic Competition and Lifecycle Management
9.9.2 Limited Potential for Dermatology, Revenue Forecast 2017-2027
9.10 Vibativ – Limited Potential for Novel Lipoglycopeptide
9.10.1 Astellas Ends its Collaboration with Theravance
9.10.2 Limited HAP Label in the US – Revenue Forecast 2017-2027
9.11 Sirturo – A New Option for Multi-Drug Resistant TB
9.11.1 Chronic Treatment Schedule and Emerging Demand Drive Revenue Growth, Forecast 2017-2027
9.12 Tedizolid – Market Leading Follow-on to Zyvox?
9.12.1 Competition Increasing: Revenue Forecast 2017-2027
9.13 Oritavancin – An Antibiotic with a Novel PK Profile
9.13.1 Single Dose Differentiation to Deliver Market Share (%), Revenue Forecast 2017-2027
9.14 Dalbavancin – Competing in a Crowded Indication
9.14.1 Sustained Growth Over the Coming 10 Years, Revenue Forecast 2017-2027
9.15 Surotomycin –Treatment for C. difficile
9.15.1 Delayed Launch to Limit Potential, Revenue Forecast 2017-2027
9.16 Nemonoxacin – Taiwan’s Global Antibacterial Drug
9.16.1 Slow Initial Growth to Accelerate with US Approval, Revenue Forecast 2017-2027

10. The Leading National Markets 2017-2027
10.1 US and China Dominate the Global Antibacterial Market, But for Different Reasons
10.2 Above-Average Growth in US: Regional Forecasts 2017-2027
10.3 China to Slump in Market Share, While Brazil and India Push on
10.4 Incidence of Infection by Country, 2016
10.4.1 Incidence of Pneumonia in National Markets – Pneumonia Predominant in America
10.4.2 Incidence of Community Acquired Urinary Tract Infections in National Markets – High Incidence Rates in the UK, US and Spain
10.4.3 Incidence of Bacterial Skin and Skin Structure Infections in National Markets – High Potential in the US
10.4.4 Incidence of Upper Respiratory Tract Infections in National Markets – Europe Leads the Way
10.5 Antibacterial Drug Consumption by Country, 2016
10.5.1 Antibacterial Drug Consumption in the Major National Markets
10.5.2 Antibacterial Drug Consumption in Some Other National Markets
10.6 The Antibacterials Market in the US
10.6.1 Continued Dominance of the US Market
10.7 The European Union Forms Second Largest Regional Market
10.7.1 Marginal Expansion in Antibacterial Spending – Market Forecast 2017-2027
10.7.2 Action to Encourage Antibacterial Drug Development in the EU
10.7.3 Italy Continues to Lead the Way in Antibiotic Use
10.7.4 The French Fascination with Expensive Antibacterial Drugs
10.7.5 Germany – Europe’s Antibiotic Steward
10.7.6 Rising Use of Antibacterials Drugs in the UK
10.7.7 Spanish Antibacterials Market to Expand from 2021 to 2027
10.8 Japan – Still the Fourth Largest National Market
10.8.1 The Pause Before Growth in the Japanese Market
10.9 Will South Korea Continue Its High Use of Antibiotics?
10.10 BRIC Nation Sales Still Expanding – Market Forecast 2017-2027
10.11 Chinese Antibacterial Market Bloated by Reported Overuse
10.11.1 Developing Antibacterials in China, for China
10.11.2 Governmental Controls Subdue Recent Growth – Market Forecast 2017-2027
10.12 Indian Market to Expand by 50% Over the Forecast Period
10.12.1 Restricting Antibiotic Use in India
10.12.2 Sustained Expansion of the Indian Market, Forecast 2017-2027
10.13 Brazilian Antibacterial Market to Double in Size
10.13.1 Brazilian Market to Be Driven by Drug Resistance
10.14 Russia: TB Prevalence to Stimulate Antibiotic Sales – Forecast 2017-2027

11. Antibacterials R&D Pipeline Review, 2017
11.1 Gram-Positive vs. Gram-Negative
11.2 Pipeline Dominated by Small Molecule Drugs
11.3 Leading Phase III Pipeline Treatment Candidates
11.3.1 Surotomycin – Broad C. difficile Treatment to Reduce Relapse
11.3.2 Baxdela (delafloxacin) – A Leading pH Activated, Broad Spectrum Fluoroquinolone
11.3.3 Solithera (solithromycin) – Fluroketolide with Favourable Side Effect Profile
11.3.4 Eravacycline – Treating Gram-Negative cUTIs and cIAIs
11.3.5 Plazomicin – Straight to PIII in Carbapenem Resistant Infections
11.3.6 Omadacycline – Another Phase III-Ready Partnership
11.3.7 Relebactam – A Novel β-Lactamase Combination
11.3.8 CEM-102 (Fusidic acid) – Cempra’s Second Pipeline Candidate
11.3.9 BC-3781- Unique Mechanism of Action at 23S?
11.4 Leading Phase II Antibacterial Drug Candidates
11.4.1 Radezolid – Apparently on Melinta’s Back-Burner for Now
11.4.2 AFN-1252: Highly Specific S. Aureus Antibacterial
11.4.3 TD-1792 – A Russian Antibacterial Medicine
11.4.4 Brilacidin – A Novel Peptide Antibacterial Agent
11.5 Inhaled Antibiotics – Advantages in Lung Infections
11.5.1 Cayston: Competition for Novartis?
11.5.2 ARIKACE – Targeting P. aeruginosa
11.5.3 Aeroquin – Better than Podhaler?
11.5.4 BAYQ3939 – Developments for Cystic Fibrosis
11.5.5 NKTR-061: Targeting Intubated Pneumonia
11.5.6 Pulmaquin: A Second Ciprofloxacin Candidate
11.5.7 AeroVanc Targets MRSA Infections
11.5.8 Inhaled Amikacin-Fosfomycin – Adjunctive Therapy for VAP
11.6 Biologics – Truly Novel Antibacterial Therapeutics
11.6.1 MK-3415A: First Antibacterial mAb to the Market?
11.6.2 KB001A – The Leading Antibody Against P. aeruginosa
11.6.3 Aridis Pharmaceuticals: Targeting P. aeruginosa and S. aureus
11.6.4 MEDI4893 – Early Stage mAb to S. Aureus
11.7 Other Classes
11.7.1 AZD0914 – Novel DNA Gyrase Inhibitor
11.7.2 MRX-I – Safer Oral Oxazolidinone to Treat MRSA
11.7.3 GSK2140944 – BTI Class of Antibiotics
11.7.4 Carbavance – to Treat CRE

12. Qualitative Analysis of the Antibacterial Industry and Market, 2017
12.1 SWOT Analysis: Strengths, Weaknesses, Opportunities and Threats Affecting Antibacterials, their Developers, Producers and Marketers
12.2 STEP Analysis: Social, Technological, Economic and Political Forces Affecting the Antibacterial Drug Industry and Market
12.2.1 Social Factors
12.2.2 Technological Developments
12.2.3 Economic Pressures
12.2.4 Political Issues
12.3 Market is Well Established and Demand Will Remain Strong
12.4 High Prevalence of Bacterial Infection Worldwide
12.5 Worldwide Demand for Antibacterials
12.6 Animal Models of Infection are Highly Predictive Compared with Other Therapeutic Fields
12.7 Cutting into a Saturated Market
12.8 Superior Benefit over Generics?
12.9 Resistance – Nature’s Patent Expiry
12.10 Acute Treatment Limits Commercial Potential
12.11 Did Big Pharma Back Away from Antibacterial Drugs?
12.12 Resistance Will Continue to Present New Targets
12.13 First Biologic Antibacterials
12.14 Potential for Smaller Firms to Capitalise
12.15 Developing Preventative Vaccines Rather Than Treatments
12.16 Antibacterial Stewardship Reduces Usage
12.17 Clinical Confusion from Inconsistent Guidance Between Regulatory Bodies
12.17.1 Therapeutic Success in European Clinical Trials
12.17.2 Primary End Points in FDA Guidelines
12.18 Reduction in Hospital Infection Rates – Reducing Demand for Antibacterial Drugs
12.19 Enticing Antibacterial Drug Discovery – Push and Pull Incentives
12.19.1 GAIN act: Post-Development Pull Incentives in the US
12.19.2 ADAPT – Building on the GAIN act
12.19.3 EMA Update Guideline – Streamlining Clinical Trials in the EU
12.19.4 Push Incentives for Antibacterial Drug Discovery with Public Funding
12.19.5 IMI: Public-Private Collaboration with GSK and AstraZeneca
12.19.6 Public Finance Pumping Money into Antibacterial Development

13. Antibacterial Drugs Market 2017 – 2027: Conclusions
13.1 Three Blockbuster Antibacterials in 2016 – Leading Brands
13.2 The Leading Branded Antibacterial Drugs in 2027
13.3 Signs of Life in the Antibacterial R&D Pipeline
13.4 Stemming the Tide of Antibacterial Drug Resistance
13.5 The Changing Face of Antibacterial Clinical Development

Appendices
Some Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form

List of Tables
Table 1.1 (Sample) Global Antibacterial Drugs Market: Revenue Forecasts by Sector ($bn), Annual Growth (%) and CAGR, 2017-2027
Table 2.1 Common Bacterial Infections and Their Causes
Table 2.2 Details of the ESKAPE Bacteria
Table 2.3 Leading Causes of Infectious Diseases Deaths Worldwide, 2010
Table 2.4 Mechanisms of Action for Antibacterial Drugs
Table 3.1 Antibacterial Drugs: Historic Global Market Size ($bn), Annual Growth (%), and CAGR (%), 2011-2016
Table 3.2 Global Antibacterial Drug Market by Sector: Market Size ($bn) and Share (%), 2016
Table 3.3 Global Antibacterial Drugs Market: Revenue Forecasts by Sector ($bn), Annual Growth (%) and CAGR, 2017-2027
Table 3.4 Antibacterial Drugs Market: Forecasted Sector Market Shares (%), 2017-2027
Table 3.5 Leading Branded Antibacterials Manufacturers: Revenues ($bn) and Market Shares (%), 2016
Table 4.1 Leading Branded Cephalosporin Antibacterial Drugs: Important Facts
Table 4.2 Cephalosporin Market by Product: Revenue ($bn) and Market Share (%), 2016
Table 4.3 Cephalosporin Market by Product: Revenue ($bn) and Market Share (%), 2021
Table 4.4 Cephalosporin Market by Product: Revenue ($bn) and Market Share (%), 2027
Table 4.5 Cephalosporin Market Forecast by Product: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 4.6 Cephalosporin Market Forecast by Product: Market Share (%), 2017-2027
Table 4.7 Rocephin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 4.8 Sulperazon Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 4.9 Zinnat/Ceftin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 4.10 Meiact Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 4.11 Flomox Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 4.12 Zinforo in-vitro Antibacterial Activity: Gram-positive and Gram-negative Bacteria
Table 4.13 Zinforo/Teflaro Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 4.14 Zeftera Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 4.15 Ceftolozane-tazobactam Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 4.16 Ceftazidime-Avibactam Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 5.1 Leading Branded Penicillin Drugs: Important Facts
Table 5.2 Penicillin Market by Product: Revenue ($bn) and Market Shares (%), 2016
Table 5.3 Penicillin Market by Product: Revenue ($bn) and Market Shares (%), 2021
Table 5.4 Penicillin Market by Product: Revenue ($bn) and Market Shares (%), 2027
Table 5.5 Penicillin Market Forecast by Product: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 5.6 Penicillin Market Forecast by Product: Market Share (%), 2017-2027
Table 5.7 Augmentin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 5.8 Zosyn/Tazocin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 5.9 Unasyn Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 5.10 Amoxil Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 5.11 Generic Amoxicillin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 5.12 Generic Amoxicillin-Clavulanic Acid Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 6.1 Leading Branded Fluoroquinolone Drugs: Important Facts
Table 6.2 Fluoroquinolone Market by Product: Revenue ($bn) and Market Share (%), 2016
Table 6.3 Fluoroquinolone Market by Product: Revenue ($bn) and Market Share (%), 2021
Table 6.4 Fluoroquinolone Market by Product: Revenue ($bn) and Market Share (%), 2027
Table 6.5 Fluoroquinolone Market Forecast by Product: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 6.6 Fluoroquinolone Market Forecast by Product: Market Share (%), 2017-2027
Table 6.7 Global Patent Expiration Dates for Avelox
Table 6.8 Avelox Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 6.9 Generic Manufacturers of Levofloxacin, 2016
Table 6.10 Cravit and Levaquin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 6.11 Vigamox Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 6.12 Ciprodex Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 6.13 Cipro/Ciprobay Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 6.14 Geninax Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 6.15 Delafloxacin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 7.1 Leading Branded Macrolides: Important Facts
Table 7.2 Macrolide Market by Product: Revenue ($bn) and Market Share (%), 2016
Table 7.3 Macrolide Market by Product: Revenue ($bn) and Market Share (%), 2021
Table 7.4 Macrolide Market by Product: Revenue ($bn) and Market Share (%), 2027
Table 7.5 Macrolide Market Forecast by Product: Revenues ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 7.6 Macrolide Market Forecast by Product: Market Shares (%), 2017-2027
Table 7.7 Biaxin/Clarith Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 7.8 Zithromax Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 7.9 Dalacin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 7.10 Dificid Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 7.11 Solithromycin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 8.1 Leading Branded Carbapenems: Important Facts
Table 8.2 Carbapenem Market by Product: Revenue ($bn) and Market Share (%), 2016
Table 8.3 Carbapenem Market by Product: Revenue ($bn) and Market Share (%), 2021
Table 8.4 Carbapenem Market by Product: Revenue ($bn) and Market Share (%), 2027
Table 8.5 Carbapenem Market Forecasts by Product: Revenues ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 8.6 Carbapenem Market Forecast by Product: Market Share (%), 2017-2027
Table 8.7 Merrem Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 8.8 Primaxin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 8.9 Invanz Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 8.10 Doribax Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 9.1 Other Leading Branded Antibacterials: Important Facts
Table 9.2 Other Classes of Antibacterial Drugs by Product: Revenue ($bn) and Market Share (%), 2016
Table 9.3 Other Classes of Antibacterial Drugs by Product: Revenue ($bn) and Market Share (%), 2021
Table 9.4 Other Classes of Antibacterial Drugs by Product: Revenue ($bn) and Market Share (%), 2027
Table 9.5 Others Market Forecasts by Product: Revenues ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 9.6 Other Agents: Market Forecast by Product - Market Share (%), 2017-2027
Table 9.7 Oxazolidinones in Mid to Late Stage Clinical Development, 2016
Table 9.8 Zyvox Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 9.9 Cubicin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 9.10 Tygacil Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 9.11 TOBI/TOBI Podhaler Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 9.12 Solodyn Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 9.13 Vibativ Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 9.14 Sirturo Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 9.15 Tedizolid Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 9.16 Oritavancin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 9.17 Dalbavancin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 9.18 Surotomycin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 9.19 Nemonoxacin Forecast: Revenue ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 10.1 Antibacterial Drug Sales by National and Regional Markets: Market Size ($bn) and Share (%), 2016
Table 10.2 Antibacterial Drug Markets: National and Regional Market Sizes ($bn), Annual Growth (%), and CAGR (%), 2017-2027
Table 10.3 Antibacterial Drug Markets: National and Regional Market Shares (%), 2017-2027
Table 10.4 Incidence of Pneumonia in National Markets, 2016
Table 10.5 Incidence of Community Acquired Urinary Tract Infections in National Markets, 2016
Table 10.6 Incidence of Bacterial Skin and Skin Structure Infections in National Markets, 2016
Table 10.7 Incidence of Upper Respiratory Tract Infections in National Markets, 2016
Table 10.8 Antibacterial Drug Consumption in the Major National Markets: DDD per Capita per Day and Absolute DDD per year, 2016
Table 10.9 Antibacterial Drug Consumption in the Smaller National Markets: DDD per Capita per Day and Absolute DDD per year, 2016
Table 10.10 US Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 10.11 EU Antibacterial Drugs Market Overall and by Leading Country (EU5): Revenue Forecasts ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 10.12 Italian Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 10.13 French Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 10.14 German Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 10.15 UK Early Stage Antibacterial Drug Developers, 2016
Table 10.16 UK Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 10.17 Spanish Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 10.18 Japanese Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 10.19 South Korean Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 10.20 Antibacterial Drugs Market in BRIC Nations: National Revenue Forecasts ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 10.21 Chinese Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 10.22 Indian Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 10.23 Brazilian Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 10.24 Russian Antibacterial Drugs Market: Revenue Forecast ($bn), Annual Growth (%), CAGR (%), 2017-2027
Table 11.1 Small Molecule Antibacterial Drug in Phase III Development, 2016
Table 11.2 Small Molecule Antibacterial Drug in Phase II Development, 2016
Table 11.3 Inhaled Antibacterial Drug Formulations in Mid to Late Stage Clinical Development, 2016
Table 11.4 Biological Antibacterial Therapeutics in Clinical Development, 2016
Table 12.1 Social, Technological, Economic, and Political Factors Affecting the Antibacterial Drug Market, 2017-2027
Table 12.2 Bacterial Related Funding for BARDA, 2011-2014
Table 13.1 World Antibacterial Drugs Market by Class: Revenues ($bn), Market Shares (%), CAGRs (%), 2016, 2021 and 2027

List of Figures
Figure 2.1 Leading Causes of Infectious Disease Deaths Worldwide, 2010
Figure 2.2 Key Events in the History of Antibacterial Drug Development
Figure 3.1 Historic Global Market Size ($bn), 2011-2016
Figure 3.2 Global Antibacterial Drug Market by Sector: Market Share (%), 2016
Figure 3.3 Global Antibacterial Drugs Market: Forecasted Sector (Class) Revenues ($bn), 2017-2027
Figure 3.4 Antibacterial Drugs Market: Forecasted Sector Market Shares (%), 2021
Figure 3.5 Antibacterial Drugs Market: Forecasted Sector Market Shares (%), 2027
Figure 3.6 Ten Leading Branded Antibacterial Manufacturers: Market Share (%), 2016
Figure 4.1 Cephalosporin Market by Product: Market Share (%), 2016
Figure 4.2 Cephalosporin Market by Product: Market Share (%), 2021
Figure 4.3 Cephalosporin Market by Product: Market Share (%), 2027
Figure 4.4 Cephalosporin Market Forecast: Revenue ($bn), 2017-2027
Figure 4.5 Cephalosporin Market: Drivers and Restraints, 2017-2027
Figure 4.6 Rocephin Forecast: Revenue ($bn), 2017-2027
Figure 4.7 Sulperazon Forecast: Revenue ($bn), 2017-2027
Figure 4.8 Zinnat/Ceftin Forecast: Revenue ($bn), 2017-2027
Figure 4.9 Meiact Forecast: Revenue ($bn), 2017-2027
Figure 4.10 Flomox Forecast: Revenue ($bn), 2017-2027
Figure 4.11 Zinforo/Teflaro Forecast: Revenue ($bn), 2017-2027
Figure 4.12 Zeftera Forecast: Revenue ($bn), 2017-2027
Figure 4.13 Ceftolozane-Tazobactam Forecast: Revenue ($bn), 2017-2027
Figure 4.14 Ceftazidime-Avibactam Forecast: Revenue ($bn), 2017-2027
Figure 5.1 Penicillin Market by Product: Market Share (%), 2016
Figure 5.2 Penicillin Market by Product: Market Share (%), 2021
Figure 5.3 Penicillin Market by Product: Market Share (%), 2027
Figure 5.4 Penicillin Market Forecast: Revenue ($bn), 2017-2027
Figure 5.5 Augmentin Forecast: Revenue ($bn), 2017-2027
Figure 5.6 Zosyn/Tazocin Forecast: Revenue ($bn), 2017-2027
Figure 5.7 Unasyn Forecast: Revenue ($bn), 2017-2027
Figure 5.8 Amoxil Forecast: Revenue ($bn), 2017-2027
Figure 5.9 Generic Amoxicillin Forecast: Revenue ($bn), 2017-2027
Figure 5.10 Generic Amoxicillin-Clavulanic Acid Forecast: Revenue ($bn), 2017-2027
Figure 6.1 Fluoroquinolone Market by Product: Market Share (%), 2016
Figure 6.2 Fluoroquinolone Market by Product: Market Share (%), 2021
Figure 6.3 Fluoroquinolone Market by Product: Market Share (%), 2027
Figure 6.4 Fluoroquinolone Market Forecast: Revenue ($bn), 2017-2027
Figure 6.5 Avelox Forecast: Revenue ($bn), 2017-2027
Figure 6.6 Cravit and Levaquin Forecast: Revenue ($bn), 2017-2027
Figure 6.7 Vigamox Forecast: Revenue ($bn), 2017-2027
Figure 6.8 Ciprodex Forecast: Revenue ($bn), 2017-2027
Figure 6.9 Cipro/Ciprobay Forecast: Revenue ($bn), 2017-2027
Figure 6.10 Geninax Forecast: Revenue ($bn), 2017-2027
Figure 6.11 Delafloxacin Forecast: Revenue ($bn), 2017-2027
Figure 7.1 Macrolide Market by Product: Market Share (%), 2016
Figure 7.2 Macrolide Market by Product: Market Share (%), 2021
Figure 7.3 Macrolide Market by Product: Market Share (%), 2027
Figure 7.4 Macrolide Market Forecast: Revenue ($bn), 2017-2027
Figure 7.5 Biaxin/Clarith Forecast: Revenue ($bn), 2017-2027
Figure 7.6 Zithromax Forecast: Revenue ($bn), 2017-2027
Figure 7.7 Dalacin Forecast: Revenue ($bn), 2017-2027
Figure 7.8 Dificid Forecast: Revenue ($bn), 2017-2027
Figure 7.9 Solithromycin Forecast: Revenue ($bn), 2017-2027
Figure 8.1 Carbapenem Market by Product: Market Share (%), 2016
Figure 8.2 Carbapenem Market by Product: Market Share (%), 2021
Figure 8.3 Carbapenem Market by Product: Market Share (%), 2027
Figure 8.4 Carbapenem Market Forecast: Revenue ($bn), 2017-2027
Figure 8.5 Merrem Forecast: Revenue ($bn), 2017-2027
Figure 8.6 Primaxin Forecast: Revenue ($bn), 2017-2027
Figure 8.7 Invanz Forecast: Revenue ($bn), 2017-2027
Figure 8.8 Doribax Forecast: Revenue ($bn), 2017-2027
Figure 9.1 Other Classes of Antibacterial Drugs by Product: Market Share (%), 2016
Figure 9.2 Other Classes of Antibacterial Drugs by Product: Market Share (%), 2021
Figure 9.3 Other Classes of Antibacterial Drugs by Product: Market Share (%), 2027
Figure 9.4 Other Agents Market Forecast by Product: Revenue ($bn), 2017-2027
Figure 9.5 Zyvox Forecast: Revenue ($bn), 2017-2027
Figure 9.6 Cubicin Forecast: Revenue ($bn), 2017-2027
Figure 9.7 Tygacil Forecast: Revenue ($bn), 2017-2027
Figure 9.8 TOBI/TOBI Podhaler Forecast: Revenue ($bn), 2017-2027
Figure 9.9 Solodyn Forecast: Revenue ($bn), 2017-2027
Figure 9.10 Vibativ Forecast: Revenue ($bn), 2017-2027
Figure 9.11 Sirturo Forecast: Revenue ($bn), 2017-2027
Figure 9.12 Tedizolid Forecast: Revenue ($bn), 2017-2027
Figure 9.13 Oritavancin Forecast: Revenue ($bn), 2017-2027
Figure 9.14 Dalbavancin Forecast: Revenue ($bn), 2017-2027
Figure 9.15 Surotomycin Forecast: Revenue ($bn), 2017-2027
Figure 9.16 Nemonoxacin Forecast: Revenue ($bn), 2017-2027
Figure 10.1 Antibacterial Drug Sales by National and Regional Markets: Market Share (%), 2016
Figure 10.2 Antibacterial Drug Market Forecasts: National and Regional Market Sizes ($bn), 2017-2027
Figure 10.3 Absolute Annual Antibacterial Drug Consumption by Nation, 2016
Figure 10.4 Per Capita Antibacterial Drug Consumption by Nation, 2016
Figure 10.5 US Antibacterial Drugs Market: Revenue Forecast ($bn), 2017-2027
Figure 10.6 EU Antibacterial Drugs Market by Leading Country (EU5): Revenue Forecasts ($bn), 2017-2027
Figure 10.7 Italian Antibacterial Drugs Market: Revenue Forecast ($bn), 2017-2027
Figure 10.8 French Antibacterial Drugs Market: Revenue Forecast ($bn), 2017-2027
Figure 10.9 German Antibacterial Drugs Market: Revenue Forecast ($bn), 2017-2027
Figure 10.10 UK Antibacterial Drugs Market: Revenue Forecast ($bn), 2017-2027
Figure 10.11 Spanish Antibacterial Drugs Market: Revenue Forecast ($bn), 2017-2027
Figure 10.12 Japanese Antibacterial Drugs Market: Revenue Forecast ($bn), 2017-2027
Figure 10.13 South Korean Antibacterial Drugs Market: Revenue Forecast ($bn), 2017-2027
Figure 10.14 Antibacterial Drugs Market in BRIC Nations: National Revenue Forecasts ($bn), 2017-2027
Figure 10.15 Chinese Antibacterial Drugs Market: Revenue Forecast ($bn), 2017-2027
Figure 10.16 Indian Antibacterial Drugs Market: Revenue Forecast ($bn), 2017-2027
Figure 10.17 Brazilian Antibacterial Drugs Market: Revenue Forecast ($bn), 2017-2027
Figure 10.18 Russian Antibacterial Drugs Market: Revenue Forecast ($bn), 2017-2027
Figure 12.1 Strengths and Weaknesses of the Antibacterial Drug Market, 2017-2027
Figure 12.2 Opportunities and Threats for the Antibacterial Drug Market, 2017-2027
Figure 12.3 Strategies and Technologies to Prevent Hospital Acquired Infections, 2016

【レポートのキーワード】

抗菌薬、抗菌剤

★調査レポート[抗菌薬の世界市場] ( Global Antibacterial Drugs Market 2017-2027 / VGAIN705057) 販売に関する免責事項
[抗菌薬の世界市場] ( Global Antibacterial Drugs Market 2017-2027 / VGAIN705057) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆